Ipilimumab, also known as an anti-CTLA-4 (cytotoxic T-cell lymphocyte-liked protein 4) antibody, was the first immune checkpoint inhibitor authorized by the FDA to treat melanoma in 2011 [11]. The gene discussed is CTLA4; the disease is melanoma.